Axsome Therapeutics, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?

Biotech Giants: SG&A Cost Management Showdown

__timestampAxsome Therapeutics, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 2014139283010811000
Thursday, January 1, 2015241928933001000
Friday, January 1, 2016634364864936000
Sunday, January 1, 2017720669199909000
Monday, January 1, 20189351522127724000
Tuesday, January 1, 201913598030161524000
Wednesday, January 1, 202028896749182933000
Friday, January 1, 202166646205219982000
Saturday, January 1, 2022159253661278139000
Sunday, January 1, 2023323123000309799000
Monday, January 1, 2024411359000
Loading chart...

Unleashing the power of data

Managing SG&A Costs: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Axsome Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc. have shown contrasting trends in their SG&A expenses from 2014 to 2023.

Axsome Therapeutics started with a modest SG&A expense of approximately $1.4 million in 2014, which skyrocketed to over $320 million by 2023, marking a staggering increase of over 22,000%. In contrast, Ultragenyx Pharmaceutical began with $10.8 million in 2014 and reached around $310 million in 2023, reflecting a growth of about 2,770%.

While both companies have seen significant increases, Ultragenyx's expenses grew at a more consistent rate, suggesting a potentially more controlled approach to managing these costs. This comparison highlights the importance of strategic financial management in the biotech industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025